All News
Juvenile Idiopathic Arthritis - NEJM Review
Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).
Read Article
A New RA Approval (8.1.2025)
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
Read Article
CKD & Osteoporosis Rx Revisited (7.25.2025)
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
Read Article
Emapalumab Approved for MAS in Still’s
On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.
Read Article
Hmmm Really? (7.11.2025)
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
Juvenile Idiopathic Arthritis - NEJM Review
Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM). https://t.co/ykI9zAUXaF
Dr. John Cush RheumNow ( View Tweet)
Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significant differences across sJIA clinical phenotypes, with dynamic changes linked to treatment response over time
ACR Open Rheumatology
https://t.co/GU5y70EXiI https://t.co/oCiKd0INuT
Links:
ACR_Journals ACR_Journals ( View Tweet)
Danish childhood vaccination registry study (1997-2020) found among 1,224,176 children w/ vaccination before age 5, w/ aluminum containing vaccines against an DPT, poliovirus, Hib (DTaP-IPV/Hib), PCV, etc found no increased risk of autoimmune dz by 8 yrs of https://t.co/9IR6AmlIT9
Dr. John Cush RheumNow ( View Tweet)
Emapalumab Approved for MAS in Still’s
On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with https://t.co/431PQlzBsV
Dr. John Cush RheumNow ( View Tweet)
Congrats to Barbara Anne Eberhard, MD, she has been awarded with the James T. Cassidy Award from the American Academy of Pediatrics (AAP). For her dedication to research/leadership in pediatric rheumatology. She is at Northwell Health’s Cohen Children’s Medical Center & Feinstein https://t.co/USGajXCMLD
Dr. John Cush RheumNow ( View Tweet)
40 kids w/ Psoriasis compared to 40 juvenile PsA pts. Those w/ jPsA were more likely to be:
- Obese/overweight (80 vs 17.5%)
- passive smoking (37.5 vs (25%)
- Signif higher ESR and CRP (P < 0.001)
- Nail PsO (65 vs 22%) https://t.co/3uBHnxZYC2 https://t.co/rW48EQta2s
Dr. John Cush RheumNow ( View Tweet)
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/hp7sFR6kLa
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Uveitis & JIA - 28 studies, 22,834 JIA pts w/ 3,381dx w/ uveitis - prevalence = 12.7%,, highest in Europeans (14.3%), lowest in Asian (6.5%). Uveitis risk factors included early age JIA onset, ANA-positive, and increased ESR. https://t.co/MxffJKvbik https://t.co/LDz60uwQTM
Dr. John Cush RheumNow ( View Tweet)
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/IDeEvitIrB
Dr. John Cush RheumNow ( View Tweet)
Don't Stop the DMARDS!!
Retrospective study of 91 JIA pts (all types; 36% oligo, 27%poly) all Rx w/ cycles of DMARD therapy. Consistently two-thirds relapsed and flared. Only one-third of JIA patients were able to remain off DMARDs. https://t.co/ifqnMKfhAe https://t.co/8JAbpO1IVe
Dr. John Cush RheumNow ( View Tweet)
Referral of 304 suspected autoinflammatory Dz (SAID) to a UK national centre for primarily adult SAID in 2022, 121 (39.5%) were diagnosed with SAID, w/ half of these having monogenic Dz. Median Dx delay was 2 to 6 yrs, worse in late-onset SAID. https://t.co/x8VOFyjuVA https://t.co/3R2HdYUlSg
Dr. John Cush RheumNow ( View Tweet)
Don't Stop the DMARDS!!
Retrospective study of 91 JIA pts (all types; 36% oligo, 27%poly) all Rx w/ cycles of DMARD therapy. Consistently two-thirds relapsed and flared. Only one-third of JIA patients were able to remain off DMARDs. https://t.co/ifqnMKfhAe https://t.co/bEqAxzRoq6
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/zrskHdw9Jx https://t.co/jkqygmfJPv
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/xrMJUgdSWv https://t.co/UJ2LZ3dU5p
Dr. John Cush RheumNow ( View Tweet)
Total serum IL 18 can help instead of CDC42 or NLCR4 genetic testing in #MAS
Several monogentic mutations in primary HLH- these panels can be available..
#EULAR2025 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
